 "Infosys, Sun Pharma, Wipro hit 52-week lows")
Infosys, Wipro and Sun Pharmaceutical Industries from the benchmark Sensex and Nifty50 indices have hit their respective 52-week lows on the bourses today.
All these three stocks were down in the range of 1%-2%, as compared to 0.16% fall in the benchmark indices at 01:21 pm.
All these three stocks were down in the range of 1%-2%, as compared to 0.16% fall in the benchmark indices at 01:21 pm.
Sun Pharma was too down 1.8% to Rs 701, also its 52-week low on NSE. The pharmaceuticals company will announce its Q2FY17 results on November 10, 2016.
The board will also consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited (formerly known as Solrex Pharmaceutical Company), all four companies being wholly owned subsidiaries of Sun Pharmaceutical Industries, with Sun Pharmaceutical Industries subject to receipt of necessary approvals.
In past three-months, the stock of Sun Pharma underperformed the market by falling 16% against less than 1% decline in Nifty50 index.
Infosys and Wipro too underperform the market post July-September (Q2FY17) results.
Wipro, which down 1.8% at Rs 450 on NSE in intra-day trade, have fallen 10% since October 21. The company had reported disappointing Q2F17 results and a sluggish IT revenue guidance for the third quarter ending December 2016 (Q3FY17).
The stock of Infosys was down 1% at Rs 970 on NSE. Since October 14, it fell 8% after the India’s second-largest software exporter has cut its annual revenue forecast for the second time in three months. The lower forecast indicates that Infosys will see flat revenue over the next six months, analysts said.
Mindtree, Mahindra Lifespace Developers and Welspun Corp are others from the BSE500 and Nifty500 index hitting their respective 52-week lows today.
The board will also consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited (formerly known as Solrex Pharmaceutical Company), all four companies being wholly owned subsidiaries of Sun Pharmaceutical Industries, with Sun Pharmaceutical Industries subject to receipt of necessary approvals.
In past three-months, the stock of Sun Pharma underperformed the market by falling 16% against less than 1% decline in Nifty50 index.
Infosys and Wipro too underperform the market post July-September (Q2FY17) results.
Wipro, which down 1.8% at Rs 450 on NSE in intra-day trade, have fallen 10% since October 21. The company had reported disappointing Q2F17 results and a sluggish IT revenue guidance for the third quarter ending December 2016 (Q3FY17).
The stock of Infosys was down 1% at Rs 970 on NSE. Since October 14, it fell 8% after the India’s second-largest software exporter has cut its annual revenue forecast for the second time in three months. The lower forecast indicates that Infosys will see flat revenue over the next six months, analysts said.
Mindtree, Mahindra Lifespace Developers and Welspun Corp are others from the BSE500 and Nifty500 index hitting their respective 52-week lows today.
| COMPANY | LATEST | 52 WK LOW | PREV LOW | PREV DATE |
| INFOSYS | 971.00 | 969.45 | 980.00 | 02-Nov-16 |
| MAHINDRA LIFE. | 410.75 | 405.50 | 414.90 | 09-Mar-16 |
| MINDTREE | 426.20 | 425.05 | 430.00 | 02-Nov-16 |
| SUN PHARMA.INDS. | 709.45 | 701.00 | 704.00 | 24-Nov-15 |
| WELSPUN CORP | 68.50 | 68.40 | 69.00 | 02-Nov-16 |
| WIPRO | 452.30 | 449.65 | 452.40 | 02-Nov-16 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%